Skip to main content

Animal Research Doesn’t Need Better Messaging. It Needs an Exit Strategy

As US regulatory agencies move toward phasing out animal testing, efforts to downplay the mistreatment of laboratory animals reflect a disconnect from current ethical and scientific standards.

Written byBarbara Stagno, RN
| 4 min read
White rats crowd to the top of a cage in a laboratory.
Register for free to listen to this article
Listen with Speechify
0:00
4:00

A recent essay in The Scientist by Americans for Medical Progress (AMP) claims that public mistrust of animal research is driven primarily by misunderstanding, not by substantive concerns. AMP attributes this confusion to the way animal advocates distort and present official records, arguing that improved communication from the industry would resolve the distrust. However, framing the issue as merely a communication challenge rather than a systemic problem fundamentally misrepresents the issue.

The problem is not poor communication by researchers, but systemic lack of transparency and accountability in animal labs. You cannot whitewash an industry that is fraught with infractions that clearly document negligence and abuse of animals in labs.

Industry defenders claim that animal research is “heavily regulated.” In reality, oversight is largely dependent on self-policing. The cornerstone of federal oversight is built on voluntary compliance through an “assurance” document submitted by the laboratory. Once this is approved, the federal oversight agency “grants considerable authority to institutions for self-regulation.” Compounding this problem, inspections by federal authorities are infrequent, often occurring only once every few years and are typically announced in advance.

Meanwhile, the vast majority of animals used in experiments—by most estimates numbering over 100 million mice—are not even covered under the US Animal Welfare Act. Internal oversight bodies, known as the Institutional Animal Care and Use Committees, are embedded within the very institutions they regulate, creating inherent conflicts of interest.

Continue reading below...

Like this story? Sign up for FREE Newsletter updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

AMP’s commentary accuses advocates of “mining” records to uncover violations, implying that such incidents are rare or selectively presented. The evidence suggests otherwise. Violations are not obscure anomalies; they are widespread and recurring.

At the Oregon National Primate Research Center, for example, inspection records and reporting document a pattern of alarming failures of negligence that led to multiple animal deaths. These serious failures are made worse because they are not unusual. Across a span of years, the facility accumulated dozens of violations, many classified as severe. These are not minor clerical errors; they are incidents involving suffering and preventable death.

Broader audits reinforce that this is not an isolated problem. A multi-state review of laboratory inspections found that dozens of facilities had documented violations in a single year, with many repeating offenses from prior years. Yet enforcement remains strikingly weak. Only a small fraction of cited facilities faced any financial penalties at all. The most common regulatory response—an “official warning”—carries no monetary consequence and appears to have little deterrent effect.

Even when penalties are issued, they are often so minimal that they function as a cost of doing business rather than a meaningful sanction. Federal enforcement resources devoted to animal welfare represent only a tiny fraction of the overall budget, and documented cases show that serious violations, including those resulting in animal deaths, frequently go unpunished. In some instances, enforcement actions have not been pursued at all due to administrative delays.

Another common claim is that critics rely on outdated information. But delays in public awareness are largely a product of the system’s opacity. Accessing records requires the filing of formal public records requests that can take months or longer to process. Even official databases lag behind real-time conditions, when they are even available. What is perceived as “old news” is often simply the first moment the public is allowed to learn what has already occurred.

Perhaps the most striking attempt to downplay these issues is the comparison of laboratory violations to incident reports at daycare centers. The analogy collapses under even minimal scrutiny. The harms documented in research facilities—botched surgical procedures, burns, dehydration, strangulation, and fatal injuries—bear no resemblance to childcare incidents.

Even basic “housekeeping” standards are not consistently met in labs. Animals have died due to overheating, drowning, exposure, and unsafe enclosures. In one recent case, dozens of rabbits drowned in preventable accidents. These are not edge cases; they are part of a documented pattern that raises serious questions about the system’s ability to safeguard even minimal welfare.

Finally, the characterization of animal advocates as militant or dangerous relies on outdated and unrepresentative examples. Contemporary advocacy is overwhelmingly grounded in lawful methods: public records requests, investigative reporting, and policy engagement. Portraying critics as extremists is an attempt to deflect attention from the substance of their concerns.

If the goal is to build public trust, improving messaging will not be enough. Trust depends on transparency, accountability, and a willingness to confront uncomfortable realities. A system that operates behind closed doors, disciplines itself, and rarely imposes meaningful consequences for failure should expect scrutiny, not deference.

More importantly, the conversation should not stop at reform. Increasingly, scientific and regulatory communities are investing in alternatives that do not rely on animal use. Emerging methods like organ-on-chip technologies, in silico studies, advanced cell cultures, and more are now being prioritized by the US FDA and NIH for their ability to deliver human-relevant outcomes. These innovations did not emerge from efforts to defend the status quo, but from recognition that better approaches are both possible and necessary.

Animal research does not need a more effective communication strategy to explain away its problems. It needs a plan to move beyond them. With over 90 percent of animal experiments failing to produce meaningful results for human health, this is a system that is seriously underperforming because it is scientifically unsound. Add to that the failed oversight of millions more animals that can be reasonably cared for, and you have an industry that no amount of reframing can improve. The question is not whether the industry communicates the right message. It is whether the system, as it currently exists, can be justified at all.

Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Barbara Sagno smiles in a headshot photo in front of green plants.

    For nearly thirty years, Barbara Stagno has dedicated her career at national animal protection organizations to exposing and challenging the use of animals in experiments. She has led numerous initiatives to highlight and combat animal suffering and mistreatment across corporate, academic, and government research facilities. In 2014, she founded Citizens for Alternatives to Animal Research & Experimentation (CAARE) to focus on the ability of scientific advancements to make powerful progress in ending the use of animals in research and testing.

    View Full Profile

Related Topics

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
The Scientist Digest cover September 2026
September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue
Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Alamar Biosciences logo
Engineering CAR-Neutrophils In Vivo to Target Glioblastoma

Engineering CAR-Neutrophils In Vivo to Target Glioblastoma

Miltenyi
Best Practices for qPCR Assay Design and Optimization

Best Practices for qPCR Assay Design and Optimization

Bio-Rad
Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

bioxcell

Products

Closeup image of a multi channel pipette dispensing pink liquid into a 96-well plate.

The ASSIST PLUS pipetting robot for affordable workflow automation

Integra Logo
Single cells in suspension

Rapidly isolate primary cells and make uniform single-cell suspensions with Corning® Cell Strainers

Corning logo
Abstract image representing cell membranes linked together.

CellBrite® Steady Membrane Stain: Cell surface staining built for real-time imaging

Biotium
sino biological logo

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays